Comparison of T-cell-depletion methods in multivariate analysis of treatment failure3-150
| . | Relative risk (95% CI) . | P . | Adjusted 5-y LFS3-151 (95% CI) . |
|---|---|---|---|
| Narrow-specificity antibodies | 1.00 | 3-152 | 25% ± 5% |
| Broad-specificity antibodies | 1.37 (1.04-1.81)3-153 | .03 | 13% ± 10% |
| Campath antibodies | 1.58 (1.26-1.99)3-153 | .0001 | 12% ± 6% |
| Elutriation | 1.65 (1.23-2.19)3-153 | .0007 | 17% ± 10% |
| Lectins | 1.47 (1.18-1.84)3-153 | .0007 | 15% ± 7% |
| . | Relative risk (95% CI) . | P . | Adjusted 5-y LFS3-151 (95% CI) . |
|---|---|---|---|
| Narrow-specificity antibodies | 1.00 | 3-152 | 25% ± 5% |
| Broad-specificity antibodies | 1.37 (1.04-1.81)3-153 | .03 | 13% ± 10% |
| Campath antibodies | 1.58 (1.26-1.99)3-153 | .0001 | 12% ± 6% |
| Elutriation | 1.65 (1.23-2.19)3-153 | .0007 | 17% ± 10% |
| Lectins | 1.47 (1.18-1.84)3-153 | .0007 | 15% ± 7% |
Other significant covariates were pretransplant disease state, patient age, performance score, donor-recipient relationship and HLA histocompatibility, year of transplantation; intensity of conditioning regimen and posttransplant immune suppression were not significantly associated with treatment failure. There was no significant interaction between prognostic factors.
Five-year probability of leukemia-free survival estimated from the multivariate model assuming a distribution of prognostic factors equal to that in the entire study population.
Reference group.
These groups are not significantly different from each other.